search
Back to results

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults (MEDI8852)

Primary Purpose

Influenza

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
MEDI8852
Placebo
Sponsored by
MedImmune LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Influenza focused on measuring Influenza, Flu, Flu A, Influenza A

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age 18 through 65 years at the time of screening
  2. Weight ≥ 45 kg and ≤ 110 kg at screening
  3. Healthy by medical history, physical examination, and baseline safety laboratory studies.
  4. Systolic blood pressure (BP) < 140 mm Hg and diastolic BP < 90 mm Hg at screening
  5. Electrocardiogram without clinically significant abnormalities at screening
  6. Able to complete the follow-up period through Day 101 as required by the protocol
  7. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 28 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study

Exclusion Criteria:

  1. Acute illness, including fever > 99.5°F, on day prior to or day of planned dosing
  2. Any drug therapy within 7 days prior to Day 1 (except contraceptives or a single use of acetaminophen, aspirin, antihistamine. and other nutritional supplements that have not been taken for at least 30 days prior to enrollment, are not exclusionary.
  3. Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 2 months prior to screening
  4. Receipt of immunoglobulin or blood products within 6 months prior to screening
  5. Receipt of any vaccine within 14 days prior to investigational product dosing or planned receipt of any influenza vaccine within 100 days after investigational product dosing
  6. Either history of active infection with hepatitis B or C or positive test for hepatitis C or for hepatitis B surface antigen at screening
  7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or serum creatinine above the upper limit of normal or hemoglobin, white blood cell count, or platelet count below the lower limit of normal at screening
  8. History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 5 years
  9. Pregnant or nursing mother
  10. History of alcohol or drug abuse within the past 2 years tha OR positive Class A drug screen for amphetamines, barbiturates, opiates, or cocaine at screening.

Sites / Locations

  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

MEDI8852

Placebo

Arm Description

MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.

Solution containing no active ingredients

Outcomes

Primary Outcome Measures

Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852
Occurrence of adverse events, serious adverse events, adverse events of special interest, and new onset chronic disease.
Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852
Clinical laboratory assessments (ie, serum chemistry, hematology, and urinalysis)

Secondary Outcome Measures

Pharmacokinetics of MEDI8852 in serum: terminal-phase elimination (t½)
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Pharmacokinetics of MEDI8852 in serum: systemic clearance (CL)
This variable will be estimated for MEDI8852 in the IV cohorts where the data allows.
Pharmacokinetics of MEDI8852 in serum: time to maximum serum concentration (Cmax)
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Pharmacokinetics of MEDI8852 in serum: area under the concentration time curve from 0 to t (AUC 0-t) and from 0 to infinity (AUC 0-inf)
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Incidence of anti-drug antibody to MEDI8852 in serum
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Pharmacokinetics of MEDI8852 in serum:volume at steady state (Vss)
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.

Full Information

First Posted
December 23, 2014
Last Updated
July 10, 2015
Sponsor
MedImmune LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02350751
Brief Title
Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults
Acronym
MEDI8852
Official Title
A Phase 1 Double-blind, Single-dose, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MedImmune LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects.
Detailed Description
This is a phase 1, single-dose, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects. Approximately 40 subjects will be entered to receive treatment across 4 fixed dose cohorts at 1 site. Investigational product will be delivered intravenously (IV). A total of 4 different dose levels of investigational product will be evaluated across the cohorts. Subjects will be followed for approximately 100 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
Influenza, Flu, Flu A, Influenza A

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
94 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MEDI8852
Arm Type
Experimental
Arm Description
MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Solution containing no active ingredients
Intervention Type
Drug
Intervention Name(s)
MEDI8852
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852
Description
Occurrence of adverse events, serious adverse events, adverse events of special interest, and new onset chronic disease.
Time Frame
100 days postdose
Title
Number of Participants with Adverse Events as a Measure of Safety and tolerability of MEDI8852
Description
Clinical laboratory assessments (ie, serum chemistry, hematology, and urinalysis)
Time Frame
28 days postdose
Secondary Outcome Measure Information:
Title
Pharmacokinetics of MEDI8852 in serum: terminal-phase elimination (t½)
Description
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Time Frame
100 days postdose
Title
Pharmacokinetics of MEDI8852 in serum: systemic clearance (CL)
Description
This variable will be estimated for MEDI8852 in the IV cohorts where the data allows.
Time Frame
100 days postdose
Title
Pharmacokinetics of MEDI8852 in serum: time to maximum serum concentration (Cmax)
Description
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Time Frame
100 days postdose
Title
Pharmacokinetics of MEDI8852 in serum: area under the concentration time curve from 0 to t (AUC 0-t) and from 0 to infinity (AUC 0-inf)
Description
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Time Frame
100 days postdose
Title
Incidence of anti-drug antibody to MEDI8852 in serum
Description
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Time Frame
100 days postdose
Title
Pharmacokinetics of MEDI8852 in serum:volume at steady state (Vss)
Description
This variable will be estimated for MEDI8852 in the IV cohorts where the data allow.
Time Frame
100 days postdose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 through 65 years at the time of screening Weight ≥ 45 kg and ≤ 110 kg at screening Healthy by medical history, physical examination, and baseline safety laboratory studies. Systolic blood pressure (BP) < 140 mm Hg and diastolic BP < 90 mm Hg at screening Electrocardiogram without clinically significant abnormalities at screening Able to complete the follow-up period through Day 101 as required by the protocol Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 28 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study Exclusion Criteria: Acute illness, including fever > 99.5°F, on day prior to or day of planned dosing Any drug therapy within 7 days prior to Day 1 (except contraceptives or a single use of acetaminophen, aspirin, antihistamine. and other nutritional supplements that have not been taken for at least 30 days prior to enrollment, are not exclusionary. Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 2 months prior to screening Receipt of immunoglobulin or blood products within 6 months prior to screening Receipt of any vaccine within 14 days prior to investigational product dosing or planned receipt of any influenza vaccine within 100 days after investigational product dosing Either history of active infection with hepatitis B or C or positive test for hepatitis C or for hepatitis B surface antigen at screening Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or serum creatinine above the upper limit of normal or hemoglobin, white blood cell count, or platelet count below the lower limit of normal at screening History of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 5 years Pregnant or nursing mother History of alcohol or drug abuse within the past 2 years tha OR positive Class A drug screen for amphetamines, barbiturates, opiates, or cocaine at screening.
Facility Information:
Facility Name
Research Site
City
Overland Park
State/Province
Kansas
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
28844541
Citation
Mallory RM, Ali SO, Takas T, Kankam M, Dubovsky F, Tseng L. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. Biologicals. 2017 Nov;50:81-86. doi: 10.1016/j.biologicals.2017.08.007. Epub 2017 Aug 23.
Results Reference
derived

Learn more about this trial

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

We'll reach out to this number within 24 hrs